Publications

1. GVS advice extension further conditions for elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®)

   The National Health Care Institute has completed its assessment whether the further conditions of ...

   Report | 21-03-2022

2. Package advice cabozantinib in combination with nivolumab (Cabometyx-Opdivo®)

   The National Health Care Institute advises the Minister to include cabozantinib in combination with nivolumab (Cabometyx® in ...

   Report | 14-03-2022

3. GVS advice liraglutide (Saxenda®), extension of further conditions for certain people with an extremely increased weight-related health risk

   The National Health Care Institute advises the Minister to extend the List 2 conditions for liraglutide (Saxenda®). The ...

   Report | 24-02-2022

4. GVS advice vericiguat (Verquvo®) for the treatment of symptomatic chronic heart failure

   The National Health Care Institute advises the Minister not to include vericiguat (Verquvo®) in the Medicine Reimbursement System ...

   Report | 24-02-2022

5. GVS advice on cenobamate (Ontozry®) for the adjunctive treatment of focal-onset seizures

   The National Health Care Institute advises the Minister to include cenobamate (Ontozry®) in List 1A of the GVS. Cenobamate is ...

   Report | 22-02-2022

6. GVS advice ofatumumab (Kesimpta®) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS)

   The National Health Care Institute advises the Minister to include ofatumumab (Kesimpta®) on List 1B of the GVS. Ofatumumab is ...

   Report | 10-02-2022

7. Package advice tisagenlecleucel (Kymriah®) for the treatment of r/r DLBCL

   The National Health Care Institute has completed its reassessment whether tisagenlecleucel (Kymriah®) can be included in the ...

   Report | 25-01-2022

8. Package advice tucatinib (Tukysa®)

   The National Health Care Institute has completed its assessment whether tucatinib (Tukysa®) in combination with trastuzumab and ...

   Report | 17-01-2022

9. Package advice acalabrutinib (Calquence®) for the treatment of chronic lymphatic leukaemia

   The National Health Care Institute has completed its assessment whether acalabrutinib (Calquence®) can be included in the insured ...

   Report | 17-01-2022

10. GVS advice on volanesorsen (Waylivra)

    The National Health Care Institute advises the Minister to include volanesorsen on List 1B of the GVS. Volanesorsen (Waylivra®) ...

    Report | 10-01-2022